{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Innovation to Impact: Drug Development, AI, and Regulatory Strategy","title":"Biology, Loops, and Decision-Grade Trust","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/165f3db8\"></iframe>","width":"100%","height":180,"duration":1768,"description":"In drug development, go/no-go decisions concentrate translational risk and expose real consequences. When AI or digital biomarkers influence that call, decision-grade evidence in a regulated environment is not optional. This episode sits in the moment every executive recognizes: the slide is on the screen and someone asks, “Do we advance?” Here’s the tension. We love the word validated, but what happens when the next dataset disagrees? We introduce a practical discipline we call the decision warranty: clear scope, clear evidence chain, clear boundaries, and explicit triggers for pause, rerun, or escalation. Someone has to own that call. Takeaway: if you cannot write the stop triggers and the decision owner on one page, do not let the tool move the decision.  If you liked this episode, steal the monthly cheat sheet at Innovation2Impact Newsletter (we do the digging, you keep the credit). ","thumbnail_url":"https://img.transistorcdn.com/Y1nZWqMkxS4Ee17tcD9y_wgj4JgHPHGNBpdmmK5mKz0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZTcz/OTlhZDEzZTZhODdi/ZDM5OGU2MTdiYWEx/YTBmNy5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}